AbbVie sours on $55B Shire deal after tax changes
By The Associated Press - AP - Thu Oct 16, 8:59AM CDT
AbbVie's board is telling shareholders to vote against its own $55 billion takeover bid for the Irish drugmaker Shire after the U.S. made reincorporating overseas a less lucrative tax maneuver.
MDT: 61.81 (-0.44), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96)
AbbVie Board To Shareholders: Vote No On Shire Buy
at Investor's Business Daily - Thu Oct 16, 12:22AM CDT
AbbVie (ABBV) late Wednesday said that its board of directors recommendation that shareholders reject a planned $55 billion buy of Shire Pharmaceuticals. The board citing new Treasury rules issued Sept. 22 making tax inversion deals less attractive....
AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), MDT: 61.81 (-0.44), COV: 85.50 (-0.36), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), ABBV: 52.90 (-1.73)
Shire Falls, AbbVie Questioned On Buyout Backtrack
at Investor's Business Daily - Wed Oct 15, 12:11PM CDT
Shares of specialty drugmaker Shire plummeted 23% on the stock market today after word got out late Tuesday that big pharma AbbVie is reconsidering its $55 billion buyout of the company. Shire (SHPG) confirmed the reports Wednesday morning with a...
ABT: 39.99 (-0.02), AZN: 67.56 (-0.85), PFE: 27.70 (-0.49), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), MYL: 48.77 (+1.39), ABBV: 52.90 (-1.73)
Stocks Dive, Then Pare Losses; Shire, Expedia, KeyCorp Crumble
at Investor's Business Daily - Wed Oct 15, 9:37AM CDT
Stocks shaved early losses but remained down hard Wednesday as weak economic data hammered away at investor confidence. The S&P 500 showed a 1.7% loss, up from a more than 2% dive in early trade. The Dow Jones industrial average recovered to a 1%...
NFLX: 361.70 (-86.89), EBAY: 47.88 (-2.36), AXP: 80.24 (-0.69), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), TRIP: 79.52 (+0.63), EXPE: 75.08 (+0.98), ABBV: 52.90 (-1.73), KEY: 12.19 (+0.05), INTC: 30.85 (-0.42)
After Yesterday's Decline of 1.25%, Salix Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 14, 4:03PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $129.91 to a high of $137.99. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $135.09 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SLXP: 137.38 (+4.96)
IBD 50: Medical, Internet Companies Top Q3 Estimates
at Investor's Business Daily - Mon Oct 13, 6:15PM CDT
Health care and Internet companies are expected to have some of the strongest third-quarter profit gains in the IBD 50. The consensus analyst estimates for medical leaders Gilead Sciences (GILD) and Lannett (LCI) exceed 200% growth. The June-quarter...
AMBA: 38.76 (+0.16), BIIB: 302.74 (-2.95), ACT: 222.07 (+4.83), VIPS: 189.33 (+3.65), YY: 76.37 (+3.97), SWKS: 51.53 (+1.93), FB: 72.63 (-0.58), AKRX: 35.80 (+0.85), KSU: 116.41 (+0.84), SLXP: 137.38 (+4.96), ATHM: 46.51 (+1.39), LCI: 41.66 (+1.36), ABC: 75.02 (-1.00), GILD: 96.88 (+0.72), AVGO: 75.60 (+3.05)
Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire
PR Newswire - Mon Oct 13, 7:30AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Arrowhead Research Corp. (NASDAQ: ARWR), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), HCA Holdings, Inc. (NYSE: HCA) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7111-100free.
HCA: 68.23 (+3.39), BIIB: 302.74 (-2.95), ARWR: 7.02 (+0.55), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96)
Salix Pharmaceuticals Partnering 2009 Industry Shares, Size, Trend, Analysis, and Forecasts to 2014 by Researchmoz
PRWeb - Sat Oct 11, 11:30PM CDT
The Partnering Agreements with Salix Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.
SLXP: 137.38 (+4.96)
Allergan Raises Outlook amidst Valeant Takeover Attempts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:20PM CDT
Allergan Inc. (AGN) raised its third quarter 2014 and full year 2014 earnings guidance.
AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), SLXP: 137.38 (+4.96)
Salix's Rectal Foam Uceris Receives Final FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 5:30PM CDT
Salix Pharmaceuticals, Ltd. (SLXP) announced that the FDA has granted final approval for Uceris rectal foam for the induction of remission in patients with active mild to moderately distal ulcerative colitis.
AGN: 178.00 (+0.41), VRX: 118.54 (+4.20), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96)
Salix Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.08%
Comtex SmarTrend(R) - Thu Oct 09, 4:57PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $140.13 to a high of $146.57. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $141.81 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SLXP: 137.38 (+4.96)
Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 2:52PM CDT
Healthcare companies have been completing merger and acquisitions this year at record pace to counter ongoing patent cliff troubles, as well as political gridlock in the U.S. over corporate tax reform. Activist investor Bill Ackman and his hedge...
DRTX: 23.60 (-0.03), AGN: 178.00 (+0.41), VRX: 118.54 (+4.20), ACT: 222.07 (+4.83), SLXP: 137.38 (+4.96)
Allergan Steeply Raises Guidance, Taunts Valeant
at Investor's Business Daily - Thu Oct 09, 10:56AM CDT
Specialty drugmaker Allergan raised its guidance Thursday and took the opportunity to say yet again that Valeant Pharmaceuticals' hostile bid for the company was too low. Allergan (AGN) stock nonetheless was flat in morning trading on the stock...
AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), SLXP: 137.38 (+4.96)
Salix Pharmaceuticals wins US FDA's approval for UCERIS 2mg rectal foam for mild-to-moderate distal ulcerative colitis
M2 - Thu Oct 09, 9:09AM CDT
Medical company Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Wednesday the receipt of the US Food and Drug Administration's (FDA) final approval for UCERIS (budesonide) 2mg rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge.
SLXP: 137.38 (+4.96)
FDA Approves UCERIS(R) (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis
Business Wire - Wed Oct 08, 7:30AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has granted final approval for UCERIS(R) (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.
SLXP: 137.38 (+4.96)
Salix Pharmaceuticals Partnering 2009 - 2014, New Report Launched
M2 - Wed Oct 08, 7:05AM CDT
Market Research Reports, Inc. has announced the addition of "Salix Pharmaceuticals Partnering 2009-2014" research report to their website http://www.MarketResearchReports.com
SLXP: 137.38 (+4.96)
Salix, Actavis Among Big Cap Pharmas In Merger Mambo
at Investor's Business Daily - Tue Oct 07, 6:33PM CDT
A one-on-one tango has since turned into a full-on hoedown as several major pharmaceutical companies continue to change partners on the M&A floor, with Valeant Pharmaceuticals (VRX) and Pershing Square Capital Management reportedly upping their bid...
DRTX: 23.60 (-0.03), AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), GILD: 96.88 (+0.72), JAZZ: 150.26 (+3.95), SLXP: 137.38 (+4.96), ABBV: 52.90 (-1.73), BMY: 49.22 (+0.26)
Salix Pharmaceuticals
at Investor's Business Daily - Tue Oct 07, 5:59PM CDT
Salix Pharmaceuticals (SLXP), seen as a possible target for Actavis or Allergan, closed down 2.4%, but rose 1% late on the Valeant report.
SLXP: 137.38 (+4.96)
Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene
at Investor's Business Daily - Tue Oct 07, 5:33PM CDT
Actavis has made acquisitions to transform from generic-focused drugmaker into a bigger player in prescription drugs and now finds itself in an enviable position -- thriving, with its home base in Ireland. Expected to generate $15 billion in revenue...
DRTX: 23.60 (-0.03), AGN: 178.00 (+0.41), PRGO: 145.69 (-0.16), VRX: 118.54 (+4.20), ACT: 222.07 (+4.83), PFE: 27.70 (-0.49), SLXP: 137.38 (+4.96), MYL: 48.77 (+1.39), TEVA: 51.56 (+1.47)